Life Sciences Archive » December, 2022

Life Sciences - December, 2022

240 articles

• The Most-Read Legal Industry Law360 Guest Articles Of 2022
• $1.35M Atty Fee Proposed For Calif., Del. Drug Trial Suits
• ITC Says Apple Watch Infringes Patents But Holds Off On Ban
• 11th Circ. Says Fla. Vaccine Requirement Appeal Isn't Moot
• The Top Patent Damages Awards Of 2022
• Insurers Slam Scouts Plan; FTX To Start Clawback Actions
• French Medical Co. Wants €4.2M Award Over Failed Expansion
• Syngenta, Corteva Pesticide Antitrust Cases Consolidated
• The Biggest Moves In Cannabis Law And Policy From 2022
• Mich. High Court Won't Fast-Track AG's Eli Lilly Insulin Probe
• Key Developments From State Attorneys General In 2022
• DC Circ. Urged To Overturn Endo-Impax Opioid Deal Win
• 6th Circ. Blocks Ky. Abortion Clinic 'Buffer Zone,' For Now
• Athenahealth Whistleblowers Lose Atty Fee Bids In 1st Circ.
• 2022 Law And Policy Highlights In Digital Health Care
• 6th Circ. Tosses 5 Cases Over COVID-19 Insurance Claims
• Fed. Circ. Won't Revive Genentech Lung Disease Patents
• PwC Pins Blame On Valeant In Securities Fraud Suit
• What 3 Legal Industry Trends From 2022 Mean For Next Year
• UK Litigation Roundup: Here's What You Missed In London
• Chancery Tosses AmerisourceBergen Opioid Suit
• Are Winds Of Change Finally Blowing On Patent Eligibility?
• Amgen Fights HHS' Drug Discount Claims At DC Court
• Drugmaker Dinged For Flouting Del. Court's Counsel Rule
• Yoga Video Co. Gaia Faces Investor Suit Over SEC Probe
• UnitedHealth Faces ERISA Suit Alleging Overcharging Scheme
• The Largest Securities Settlements Announced In 2022
• EPA Sued Over 'Inaction' On Endocrine-Disrupting Pesticides
• Judge Trims Boston Scientific Investor's Stock Suit
• Fed. Circ. Revives Patents In IP Suit Over Opioid Generic
• Accused 'Pill Mill' Doc Asks 3rd Circ. To Toss Guilty Plea
• A Numerical Analysis Of FDA Warning Letters In 2022
• Learning From This Year's Legal Industry Discrimination Suits
• Wash. AG Says Kroger, Others Helped Fuel Opioid Epidemic
• Top Government Contracts Cases Of 2022
• Biggest Developments In Antitrust Conduct Cases In 2022
• The 6 Biggest 1st Circ. Rulings Of 2022
• Biden Names 6 New District Court Picks
• Walmart, CVS, Albertsons To Pay $189M In NM Opioid Deals
• 3M, DuPont And Others Sued Over Fire Foam Water Pollution
• BioTelemetry, CardioNet To Pay $44.8M To Settle FCA Case
• Ill. Judge Won't Upset $363M Sterigenics Emissions Verdict
• WTO Dispute Roundup: New Delays Heading Into 2023
• DLA Piper Sued For Malpractice After Gummy Deal Collapses
• 2nd Circ. Says FCA Claims Against Fresenius Already Public
• J&J Expert Says Talc Claims Process To Move Swiftly
• The Future Of Legal Ops: AI Has Important Role To Play
• 4 Proactive Strategies For 'Rocket Docket' Discovery In SDNY
• Teva, Glenmark Get May 2024 Price-Fixing Criminal Trial
• Plaintiffs Seek OK On $255M Juul MDL Economic Settlement
• Monsanto Wins 11th Circ. Redo Of Ga. Doctor's Roundup Case
• Biotech CEOs Lied About HIV Drug, Feds Say
• How DC Became A Consumer Protection Pioneer
• Revived Calif. Bill Would Decriminalize Psychedelics
• Florida's Medical Marijuana Industry: 2022 In Review
• Philips Says It Didn't Mislead CPAP Cleaner Co.'s Customers
• Jazz Pharma Asks Fed. Circ. To Reverse Orange Book Delisting
• Planned Parenthood Slams 'Deficient' Texas Privilege Claims
• Catching Up With Delaware's Chancery Court
• Express Scripts Says Sanction Bid A Tactic Of A Failed Case
• Bayer Asks Chancery To Toss Merck's Talc Liability Suit
• Novartis And Grifols Say Abbott Can't Tank HIV Test Patent
• 9 Considerations For Landlords Renting To Cannabis Cos.
• 5 Drug Pricing Issues To Watch In 2023
• Psychedelic Biz Pledges No IP Suits Over Natural Mescaline
• Judge OKs $75M Ch. 11 Loan From Clovis Secured Lender
• Juul's Massive E-Cig Marketing Deal Won't Derail Altria Trial
• USTR Seeks More Data As WTO Delays COVID-19 IP Vote
• How EU's New Pharma Incentives May Affect US Cos.
• Real Estate Rumors: Vigilant, ABS Partners, DR Horton
• Opana End-Payors Get Final OK Of $15M Impax Deal
• Janssen Thwarting Docs Order In Kickback Suit, Court Told
• Practical Steps For Companies Facing PFAS Risks
• What Really Doomed Kidney Test Patents In Fed. Circ. Ruling
• Leading Conservative Atty Retires After Decades At Jones Day
• Thompson Hine Adds New Enviro Partner In Atlanta
• Health Hires: Barnes & Thornburg, BillionToOne
• Increasing Law Firm Polarization Will Degrade Rule Of Law
• Cannabis Research Center To Open In Chicago
• TCPA Verdict Remand Is A Boon For Class Action Defendants
• FDA Warns CBD Cos. About COVID Claims
• Judge Breathes 6 Months Of Life Into AstraZeneca Patent
• FDA Extends Inspection Delay Guidelines To Medical Devices
• The Biggest Patent Rulings Of 2022
• 3rd Circ. Won't Revive Health Plans' Suits Over Opioid Drug
• Navigating Uncertainties In Section 340B Drug Pricing
• 3 PTAB Cases Offer Guidance For Drafting Method Claims
• Clovis Oncology Ch. 11 Loan Process Down To The Wire
• Chancery Says AmerisourceBergen Suit Not Time-Barred
• PerkinElmer Says Lab Must Face Claim Over COVID Gear
• Breast Implant Maker Gets Injury Suit Tossed
• Best Practices For Cannabis Cos. Managing A Product Recall
• Coca-Cola Distributor Fired Medical Pot Patient, Suit Alleges
• Alleged Insider Trader Sues For Fees In Del. Bioverativ Suit
• HHS Pans Pfizer's 'Far-Fetched' Kickback Views At High Court
• Texas Justices Say No Remote Jurors In J&J Pelvic Mesh Trial
• Masimo Launches Counterattack In Apple Watch IP Fights
• Fed. Circ. Pauses 'Orange Book' Delisting For Jazz Drug
• Enviro Groups Allege EPA Delayed Ethylene Oxide Air Rules
• Georgia Agencies Sued For Failure To Cover Trans Benefits
• Navigating The Unique Challenges Of An OIG Investigation
• What To Expect From Colo. Therapeutic Psychedelics Law
• Merck's $1.35B Merger With Biotech Faces Investor Suits
• Why States Need Clear Standards For Cannabis Testing Labs
• LabSolutions CEO Guilty In $187M Telemed Billing Scheme
• Two Lenders Vie For $75M Clovis Oncology Ch. 11 DIP Loan
• 8th Circ. Won't Upend $21M Biomet Hip Implant Verdict
• How To Deal With Difficult Clients, Practically And Ethically
• Investment Cos. Say CBD Biz Defrauded Them Of $4.7M
• DeSantis Petitions Fla. Justices For COVID-19 Vax Grand Jury
• Illumina Tells FTC Commissioners Grail Deal Will Save Lives
• 7 Firms Lead Metals, Pharma And Wellness Co. SPAC Deals
• Teva, Apotex Win Ax Of Patents In Sleep Drug Suit
• Medical Device Co. Strikes $14.5M Deal To Settle FCA Claims
• Glove Co. Wants $68M Labor Probe Concealment Suit Ended
• Pesticide Giants Ask To Exterminate FTC's 'Pay-To-Block' Suit
• 2 Firms Drive Up To $6B Deal For Nimbus' Psoriasis Drug Biz
• Ravgen Fetal DNA Testing Patent Survives PTAB Review
• Munger Tolles & Olson Promoting 3 To Partner In 2023
• Ga. Family Sues Over Father's Kratom-Linked Death
• 6th Circ. Rejects Challenge To Opioid MDL Fee Order
• Lab Director Gets 5 Months For Duping FDA Before Outbreak
• Vape Co. Can't Undo FDA Denial Of Flavored E-Cig Fluids
• Juul To Pay Pa. $38.8M To Settle Youth Marketing Claims
• Allergan Snags Win In Investor Class Action Over Implants
• Deliberations Start In $187M Genetic Testing Scheme
• Biz Owner Can't Nix 50 Cent's Suit On Penile Enhancement Ad
• LegitScript Can't Pause Drug Price Check Blacklisting Suit
• Tulane, Insurer Get More Time For COVID Coverage Settlement
• CR Bard, AngioDynamics Spar Over Timing Of Damages Trial
• Biotech Co. Gets Investor Suit Over Failed COVID Test Tossed
• Atty's Real Estate Cos. Want Out Of Ex-NFL Player's PPE Suit
• Biosciences Co. Says 3 Ex-CEOs Pilfered Cardiac Test IP
• Walgreens And CVS Finalize $10.7B Opioid Fallout Deal
• Catching Up With Delaware's Chancery Court
• Fed. Circ. Rulings That Gave Patent Law A New Spin In 2022
• Federal Courts Should Adopt Supreme Court's Amicus Stance
• The 2022 Law360 Pulse Leaderboard
• Top Firms Make Growth A Priority For 2023
• Detroit Says Updated Cannabis Ordinance Is Constitutional
• Clovis Oncology Hits Ch. 11 With $754.5M Debt And Sale Plans
• Amgen To Buy Ireland's Horizon Therapeutics For $28B
• 3rd Circ. Affirms Takeda's Nix Of Prevacid Antitrust Claims
• Medical Device Co. Blames Judge For Sinking Patent Case
• Centene Stockholder Sues In Alleged Medicaid Fraud Scheme
• ITC Delays Final Ruling On Apple Watch Import Ban
• Life Sciences Co. Says Ex-Worker, Rival Swiped Trade Secrets
• Philips Wants Latest CPAP Foam MDL Complaint Tossed
• J&J Unit Hit With $12M Verdict In Spinal Implant IP Suit
• Novavax Brass Sued In Del. For Touting Failed COVID Vaccine
• PTAB Wipes Out Sex-Selection Patent In Pig Breeding IP Row
• Drugmaker's Knowledge Of Suits Bars Coverage, Court Told
• 1st Circ. Revives Puerto Rico Urologists' Antitrust Case
• Texas Abortion Provider Gets Bounty-Hunter Suit Tossed
• Pa. Cannabis Co. Didn't Pay For Plant Growth IP, Firm Says
• Geico Seeks $2.4M From Health Centers For False Claims
• 6th Circ. Takes On Kentucky Abortion Clinic's 'Buffer Zone'
• AbbVie Sales Rep Alleges Age Discrimination In Promotions
• Lab Exec Seeks Probation For FDA Fraud Tied To Outbreak
• Texas AG Says Mallinckrodt Trust Can't Be Used For Atty Pay
• 1st Circ. Doubts Error In Hedge Fund Priest's Fraud Verdict
• Teva's UK Appeal Over Patent For MS Drug Gilenya Falls Flat
• FDA Graphic Cigarette Warnings Go Up In Smoke
• Merck Sheds Nearly 1,200 Shingles Vaccine Suits
• Ex-Florida Pain Doctor Gets 3½ Years For Insys Kickbacks
• Novartis Can't Beat Suit Over Eye Injection Treatment
• Ga. County Says It 'Dropped Ball' Approving Sterigenics Plant
• Ex-Theranos Exec Balwani Gets Nearly 13 Years For Fraud
• Gov't Recommends High Court Review Intent In FCA Cases
• Justices Seem Disinclined Toward Any Major FCA Upheaval
• 5th Circ. Revives Some Medtronic Pacemaker Claims
• EU Also Probing Cochlear's Hearing Implant Merger
• Ga. Co. Agrees To Pause E-Cigarette Sales In Feds' Case
• Science Investing Biz Sells 5% Stake In Biotech Co. For €145M
• Arnold & Porter Punished For Opioid Lapses, Averts Contempt
• Fla. Court Axes Zantac MDL Claims, Citing Lack Of Experts
• Juul Cuts Deal To End MDL On Eve Of Bellwether Trial
• Balwani May Get More Prison Time Than Holmes, Experts Say
• Justices Skeptical About Limits On Gov't FCA Dismissal Right
• 9th Circ. Backs CVS' Win Over $121M Drug Overcharge Claim
• Juul Founders Say NY's Illict Marketing Claims Must Fall
• Judge Shrinks J&J's Potential Damages Recovery In IP Row
• FTC Staff Warn Against Changing Juul-Altria Standard
• Fed. Circ. Wary Of Reviving Gilead's Lexiscan IP Suit
• Dems Press Patent Office On Pharma 'Abuse' Of System
• Gov't Says Gilead Can't Shake HIV Drug Patent Suit
• USTR Calls For More Time On IP Waiver Expansion Decision
• Lipitor Buyers Say Calif. Group Can't Move Claims Out Of NJ
• L'Oreal Case Highlights Legal Risks Of Anti-Aging Claims
• Teva Case Aims Europe's Pharma Crackdown At IP Loophole
• Elizabeth Holmes Asks To Stay Out Of Prison During Appeal
• Brown Rudnick Hires New UK IP Chief From Fieldfisher
• Pfizer, BioNTech Seek To Nix Moderna Vax IP Suit, Countersue
• Actelion Hit With RICO Suit Over Blood Pressure Drugs
• Del. Court Won't Pause 'Orange Book' Delisting
• Drug Co. Must Provide Docs In False Probiotic Claims Case
• Essilor To Pay $23.8M To End Calif. Insurance Fraud Probe
• Facing Potential ITC Ban, Apple Files IP Suit Over Health Tech
• DuPont Says It Didn't Contaminate Fla. City Well Water
• Catching Up With Delaware's Chancery Court
• EU Wants Illumina To Unwind $8B Grail Deal 'Swiftly'
• CSX Must Face Rail Worker's Cancer Suit, Appeals Court Says
• 1st Circ. Skeptical Of Ex-NuVasive Rep's Noncompete Appeal
• Deal For Crypto Biz Circle Among 2 SPAC Mergers Falls Apart
• 3 Pricing Trends In Law Firm Use Of Litigation Funding
• The 2022 Law360 Pulse Prestige Leaders
• In Law Firm Race For Revenue, Top Dogs Stand Alone
• Fed. Circ. Won't Rethink Axed Stanford Kidney Test Patents
• Elizabeth Holmes Appeals Conviction, Sentence To 9th Circ.
• Doctor Repped By RFK Jr. Targets COVID Misinformation Law
• Target, Starbucks Sold Recalled Food With Bacteria, Suit Says
• CVS, Walgreens Take Aim At $650M Opioid Verdict
• CORRECTED: Cannabis REIT Wants Out Of Risky Investment Claims
• EPA Nets Deal With Ohio Steel Plant Over Lead Emissions
• Biden Signs Marijuana Research Bill Into Law
• Compliance Considerations For Virtual Ketamine Clinics
• Interest Rates Doom Lender, Crypto Winter Persists
• Pierre Fabre Accused Of Selling Cancerous Dry Shampoo
• Alcon Gets More J&J Unit Eye Surgery IP Axed At PTAB
• Seasoned Litigator Joins Baker Botts In Dallas From Foley
• Safeguarding Attorneys' Greatest Asset: Our Mental Health
• How 6th Circ. Flint Ruling Adds To 5th Amendment Case Law
• How The Amgen Case May Affect Patent Owners, Prosecutors
• Theranos Exec Balwani Wants Probation As Feds Seek 15 Yrs.
• Top Opioid Target Kroger Inks $85M Deal, With $25M For Attys
• 11th Circ. Backs Ex-Doctor's Conviction In Prescription Case
• Masimo Clarifies Some Proxy Notice Rules Hit In Del. Suit
• IP Forecast: Jury To Hear Apple-Ericsson Licensing Battle
• Biotech Co. Accuses Citadel Securities, Others Of Spoofing
• Nev. Pharma Board Fights To Keep Pot A Schedule I Drug
• NJ Judge Backs Bausch Patents On Psoriasis Drugs
• BCBS Calls New Bid To Remand Pot Coverage Suit 'Baseless'
• Ex-IP Chiefs Urge US To Focus On Next Pandemic, Not Waiver
• 10 Things To Know About The Coming EU Unified Patent Court
• Blocking A Second Punitive Damages Award In Product Cases
• Pharma Co. Slams Bid To Delay 'Orange Book' Delisting
• Trans W.Va. Medicaid Participants Urge 4th Circ. To Affirm Win
• Deals Rumor Mill: CoinDesk, News Corp., Liverpool FC
• Lab Exec Gets 1 Year For FDA Fraud Tied To Deadly Outbreak
• Payment Recovery Co. Wants Attys On Hip Implant MDL Team